Brain Complete Response to Cabozantinib prior to Radiation Therapy in Metastatic Renal Cell Carcinoma

Cabozantinib represents an established vascular endothelial growth factor- (VEGF-) tyrosine kinase inhibitor (TKI) in the treatment paradigm of metastatic renal cell carcinoma (mRCC). Its activity in mRCC patients with brain metastases (BMs) has been largely underreported in prospective clinical tri...

Descripción completa

Detalles Bibliográficos
Autores principales: Uche, An, Sila, Chad, Tanoura, Tad, Yeh, James, Bhowmick, Neil, Posadas, Edwin, Figlin, Robert, Gong, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393887/
https://www.ncbi.nlm.nih.gov/pubmed/30906615
http://dx.doi.org/10.1155/2019/6769017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393887/
https://www.ncbi.nlm.nih.gov/pubmed/30906615
http://dx.doi.org/10.1155/2019/6769017

Ejemplares similares